SEC Form 4 · accession 0001104659-18-036485
Kiniksa Pharmaceuticals International, plc · KNSA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carsten Boess
10% Owner
Period of report
May 29, 2018
Accepted (ET)
May 29, 2018 · 7:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001730430
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Shares | May 29, 2018 | C | 6,392 | $0.00 | A | 79,589 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series C Preferred SharesF2,F1 | — | Feb 9, 2018 | P | 6,392 | A | — | — | Class A Common Shares | 6,392 | 6,392 | D |
| Series A Preferred SharesF3 | — | May 29, 2018 | C | 107,050 | D | — | — | Class B Common Shares | 107,050 | 0 | D |
| Series C Preferred SharesF1 | — | May 29, 2018 | C | 6,392 | D | — | — | Class A Common Shares | 6,392 | 0 | D |
| Class B Common SharesF4 | — | May 29, 2018 | C | 107,050 | A | — | — | Class A Common Shares | 107,050 | 473,035 | D |
Explanation of responses
- F1Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.
- F2Reflects the 1-for-2.73235 share consolidation effected May 11, 2018.
- F3Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis.
- F4Each share of Class B Common Shares is convertible at any time at the election of the holder into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.